Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease

Background: Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are seen to be increased in preclinical stage of the disease. However, it is unknown if these increases transpire earlie...

Full description

Bibliographic Details
Main Author: Ashton, Nicholas J. (author)
Other Authors: Benedet, Andréa L. (author), Pascoal, Tharick Ali (author), Karikari, Thomas K. (author), Lantero-Rodriguez, Juan (author), Brum, Wagner Scheeren (author), Mathotaarachchi, Sulantha Sanjeewa (author), Therriault, Joseph (author), Savard, Mélissa (author), Chamoun, Mira (author), Stoops, Erik (author), François, Cindy (author), Vanmechelen, Eugeen (author), Gauthier, Serge (author), Zimmer, Eduardo Rigon (author), Zetterberg, Henrik (author), Blennow, Kaj (author), Rosa Neto, Pedro (author)
Format: other article
Language:eng
Published: 2022
Subjects:
Líquido cefalorraquidiano
Doença de Alzheimer
Proteínas tau
Peptídeos beta-amilóides
Tomografia por emissão de pósitrons
Biomarcadores
Cerebrospinal fluid
Phosphorylated tau
Alzheimer’s disease
Preclinical
Amyloid
Positron emission tomography
Online Access:http://hdl.handle.net/10183/239847
Country:Brazil
Oai:oai:www.lume.ufrgs.br:10183/239847

Internet

http://hdl.handle.net/10183/239847

Similar Items